Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer
September 1st 2023Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.
Read More